The Pain Patient Population

April 5, 2018 by C. Scott McMillin

Based on the vast number of prescriptions for opioid medications written by US practitioners over the past few decades, we’ve become the clear leaders in opioid prescribing.

Topics: , , ,


A New ADHD Epidemic?

March 8, 2018 by C. Scott McMillin

Of course, if you work in addiction treatment, you probably see some of these same meds being abused by young adults, often beginning in college or grad school.

Topics: ,


Strange Bedfellows in the Pharma Lobby

February 26, 2018 by C. Scott McMillin

It isn’t PhDs in the white lab coats who show up at your doctor’s office to provide false or misleading information about drug safety.

Topics: , ,


Two Perspectives on Pain

February 22, 2018 by C. Scott McMillin

We may be stuck relying on the soft stuff– therapy, support, behavior change, even spiritual growth– all those icky-squicky things that neuroscientists struggle to quantify.

Topics: , , , ,


In the News: Polypharmacy and Tom Petty

February 12, 2018 by C. Scott McMillin

It’s the result of a problem in medicine that’s been going on since before I ever started working in the field. The drugs have changed, but the results haven’t.

Topics: , ,


Drug Prices: The Blame Game

January 25, 2018 by C. Scott McMillin

As a former insurance VP once put it, you spend your day looking at spreadsheets, you forget there are real people out there depending on you.

Topics:


Gabapentin

January 8, 2018 by C. Scott McMillin

You might say the drug itself may not be that dangerous, except to our patients. 

Topics: , ,


Beware Lookalikes

December 14, 2017 by C. Scott McMillin

It’s also not too difficult to create a ‘homemade’ variety using raw ingredients purchased on the dark web and a common pill press.

Topics: , , ,


Depression Update

December 7, 2017 by C. Scott McMillin

Patients with severe substance disorders may experience depression as a result of the cumulative effects of their substance use.

Topics: , ,


Opioid Alternatives

October 16, 2017 by C. Scott McMillin

The larger issue is that most drug pricing is still market-driven, or as my endocrinologist puts it, “they charge whatever they can get away with charging.”

Topics: , ,


Subscribe to RecoverySI via Email

Join 701 other subscribers


New Content